Clinic Roundup

• Kenta Biotech, of Zurich-Schlieren, Switzerland, reported that the first patient was enrolled in a Phase I/II trial with KBSA301, a fully human antibody for the treatment of severe pneumonia caused by S. aureus. The trial will involve 44 patients suffering from severe pneumonia caused by S. aureus admitted into intensive care units around Europe. They will receive a single dose of KBSA301, or placebo, in addition to standard antibiotic therapy.